Reading Time: 1 minute
Moderna (MRNA) has proven that mRNA technology works. However, the journey from a pure pandemic profiteer to a broadly diversified biotech company requires endurance. The recent developments surrounding personalized cancer therapy represent an important milestone. When a vaccine is individually tailored to a patient's tumor, it opens up entirely new medical and commercial avenues for the company. The production of individualized medications is logistically complex and costly. It will take time before such therapies are not only medically approved...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
